The purpose of this study is to evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric subjects...
Amgen has announced that The Lancet published results from a Phase III randomized, double-blind, placebo-controlled study of Nplate (romiplostim) in...
Adults: Nplate is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1). Paediatrics: Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).
The primary objective is to evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric subjects with immune...
The primary objective of this study is to evaluate the incidence of collagen fibrosis as evidenced by trichrome staining at...
Nplate is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).
The primary objective of this study is to evaluate the safety of romiplostim as a long-term treatment in pediatric thrombocytopenic...
The primary objective is to describe the number of months with a subject platelet response over a 12 month treatment...
Amgen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of...